The estimated Net Worth of Randall J Lanham is at least $510 mil dollars as of 28 October 2018. Mr. Lanham owns over 2,900 units of Nymox Pharmaceutical Corp stock worth over $30,580 and over the last 6 years he sold NYMX stock worth over $0. In addition, he makes $478,961 as General Counsel e Director at Nymox Pharmaceutical Corp.
Randall has made over 1 trades of the Nymox Pharmaceutical Corp stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 2,900 units of NYMX stock worth $4,988 on 28 October 2018.
The largest trade he's ever made was buying 2,900 units of Nymox Pharmaceutical Corp stock on 28 October 2018 worth over $4,988. On average, Randall trades about 2,900 units every 0 days since 2018. As of 28 October 2018 he still owns at least 152,900 units of Nymox Pharmaceutical Corp stock.
You can see the complete history of Mr. Lanham stock trades at the bottom of the page.
Randall J. Lanham Esq. serves as General Counsel, Director of the Company. He has been a director since June 8, 2006. He attained his Juris Doctor from Whittier College School of Law in 1991 and a Bachelor of Science degree from the University of Delaware in 1987. Mr. Lanham has vast experience in both domestic and international corporate legal matters. Currently Mr. Lanham manages his own law office in California specializing in corporate mergers and acquisitions. In addition, Mr. Lanham has a broad base of entrepreneurial experience and currently owns and operates several small entertainment companies.
As the General Counsel e Director of Nymox Pharmaceutical Corp, the total compensation of Randall Lanham at Nymox Pharmaceutical Corp is $478,961. There are 3 executives at Nymox Pharmaceutical Corp getting paid more, with Paul Averback having the highest compensation of $2,318,000.
Randall Lanham is 55, he's been the General Counsel e Director of Nymox Pharmaceutical Corp since 2015. There are 8 older and no younger executives at Nymox Pharmaceutical Corp. The oldest executive at Nymox Pharmaceutical Corp is James Robinson, 84, who is the Independent Director.
Randall's mailing address filed with the SEC is , , , , .
Over the last 9 years, insiders at Nymox Pharmaceutical Corp have traded over $4,394,000 worth of Nymox Pharmaceutical Corp stock and bought 2,534,915 units worth $5,846,809 . The most active insiders traders include James George Robinson, Paul Averback, eErik Danielsen. On average, Nymox Pharmaceutical Corp executives and independent directors trade stock every 27 days with the average trade being worth of $9,606. The most recent stock trade was executed by James George Robinson on 2 May 2022, trading 1,151,515 units of NYMX stock currently worth $1,900,000.
nymox pharmaceutical corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. its lead drug candidate is fexapotide triflutate (nx-1207) that has completed phase iii clinical trials for the treatment of benign prostatic hyperplasia; and is in phase ii clinical trial for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. the company also develops and markets nicalert and tobacalert test strips that use urine or saliva to detect use of tobacco products. in addition, it offers alzheimalert, a proprietary urine assay that aids physicians in the diagnosis of alzheimer's disease. the company operates in canada, the united states, europe, and internationally. nymox pharmaceutical corporation was founded in 1989 and is headquartered in nassau, bahamas.
Nymox Pharmaceutical Corp executives and other stock owners filed with the SEC include: